SBC Medical Group Holdings Inc. SBC

Nasdaq; healthcare; SIC 8011, Services-Offices & Clinics of Doctors of Medicine; CIK 0001930313

A

strongest fifth of 370 graded peers in healthcare

rank 22 of 370; percentile 5.8; sampling error 2.5 points; lower is stronger


A B C D E

A, the bull




Scoreboard	
Profitability	C percentile 45.8
Solvency	A/B percentile 18.3
Growth and financing	A/B percentile 18.7
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $380.4M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered; fortress balance sheet not computable: dilution, distress
Inputs computable	9 of 14
Graded from	filings received through Apr 30, 2026 181 days before the rescan; latest periodic filing 10-Q received Aug 13, 2026
Last close	$5.18 2026-10-27; market equity $0; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 27, 2026

- Government Regulation and Environmental Matters" in this Annual Report. The Company, its subsidiaries, and the MCs also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. Environmental and social laws and regulations have tended to become increasingly stringent. There has been increased global focus on environmental and social issues and it is possible that countries may potentially adopt more stringent standards or new regulations in these areas. To the extent regulatory changes occur in the future, they could result in, among other things, increased costs to the Company, its subsidiaries, and the MCs.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 45.8						
Gross profitability	33.5%	32.3%		42.8	369	2025-12-31
Return on invested capital	41.2%	9.3%		4.8	74	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	8.1%	(6.6%)	89.7	805	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 2					
Solvency, sleeve percentile 18.3					
Twelve-month failure probability	not computable	0.07%			
firm-wide XBRL shares cannot be assigned to one ticker class					
Altman Z double-prime	8.41	(0.33)	11.4	751	2025-12-31
Net debt to EBITDA	(1.72x)	1.82x	12.8	75	2025-12-31
Interest coverage	455.26x	(4.51x)	0.6	80	2025-12-31
Current ratio	3.78x	2.94x	48.4	832	2025-12-31
Growth and financing, sleeve percentile 18.7					
Revenue growth, three-year compound	not computable	10.1%			
four annual observations are required; found 2					
Free cash flow growth, three-year compound	not computable	10.9%			
four consecutive annual FCF observations are required; found 2					
Reinvestment rate	108.5%	37.1%	28.6	104	2025-12-31
Asset growth, three years	46.9%	2.1%	8.7	697	2025-12-31
Net share issuance, one year	not computable	2.5%			
firm-wide XBRL shares cannot be assigned to one ticker class					


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Fortress balance sheet	cash minus debt is 120,940,354 USD; Altman Z is not used

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
17	Ideaya Biosciences, Inc. (IDYA)	4.3	A	
18	Tarsus Pharmaceuticals, Inc. (TARS)	4.6	A	fortress balance sheet
19	Vericel Corp. (VCEL)	4.9	A	
20	Biomarin Pharmaceutical Inc. (BMRN)	5.1	A	
21	Neurocrine Biosciences Inc. (NBIX)	5.4	A	
22	SBC Medical Group Holdings Inc. (SBC)	5.8	A	fortress balance sheet
23	SBC Medical Group Holdings Inc. (SBCWW)	5.8	A	fortress balance sheet
24	Crispr Therapeutics AG (CRSP)	6.2	A	
25	Intuitive Surgical Inc. (ISRG)	6.5	A	
26	AtriCure, Inc. (ATRC)	6.8	A	
27	United Therapeutics Corp. (UTHR)	7.0	A	

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-10-27 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(7.4%)	7.7%	42
Distance from 52-week high	(8.4%)	(28.6%)	79
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	not computable	0.28	
Sales to price	not computable	0.31	
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	(0.29)	(0.14)	42

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$184.3M
Operating cash flow, four quarters	$62.8M
Months of runway	not finite
Days since last periodic filing	76 (10-Q received Aug 13, 2026)
Median daily dollar volume, 63 sessions	$850,452

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$127.3M	2025-12-31	2026-03-27	10-K	26-127557
2	assets	us-gaap:Assets	$380.4M	2025-12-31	2026-03-27	10-K	26-127557
3	operating income	us-gaap:OperatingIncomeLoss	$67.5M	2025-12-31	2026-03-27	10-K	26-127557
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$82.1M	2025-12-31	2026-03-27	10-K	26-127557
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$31.0M	2025-12-31	2026-03-27	10-K	26-127557
6	total debt	us-gaap:LongTermDebt	$42.8M	2025-12-31	2026-03-27	10-K	26-127557
7	book equity	us-gaap:StockholdersEquity	$248.3M	2025-12-31	2026-03-27	10-K	26-127557
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$163.8M	2025-12-31	2026-03-27	10-K	26-127557
9	total debt	us-gaap:LongTermDebt	$6.6M	2024-12-31	2025-03-28	10-K	25-001062
10	book equity	us-gaap:StockholdersEquity	$195.1M	2024-12-31	2026-03-27	10-K	26-127557
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$125.0M	2024-12-31	2026-03-27	10-K	26-127557
12	net income	us-gaap:NetIncomeLoss	$51.0M	2025-12-31	2026-03-27	10-K	26-127557
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$24.7M	2025-12-31	2026-03-27	10-K	26-127557
14	assets	us-gaap:Assets	$266.1M	2024-12-31	2026-03-27	10-K	26-127557
15	current assets	us-gaap:AssetsCurrent	$231.2M	2025-12-31	2026-03-27	10-K	26-127557
16	current liabilities	us-gaap:LiabilitiesCurrent	$61.1M	2025-12-31	2026-03-27	10-K	26-127557
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	$240.4M	2025-12-31	2026-03-27	10-K	26-127557
18	liabilities	us-gaap:Liabilities	$117.1M	2025-12-31	2026-03-27	10-K	26-127557

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$2.7M	2025-12-31	2026-03-27	10-K	26-127557
20	interest expense	us-gaap:InterestExpense	$148,238	2025-12-31	2026-03-27	10-K	26-127557
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$173.6M	2025-12-31	2026-03-27	10-K	26-127557
22	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$205.4M	2024-12-31	2026-03-27	10-K	26-127557
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.4M	2025-12-31	2026-03-27	10-K	26-127557
24	current assets	us-gaap:AssetsCurrent	$184.5M	2024-12-31	2026-03-27	10-K	26-127557
25	current liabilities	us-gaap:LiabilitiesCurrent	$61.2M	2024-12-31	2026-03-27	10-K	26-127557
26	assets	us-gaap:Assets	$258.8M	2023-12-31	2025-03-28	10-K	25-001062
27	assets	us-gaap:Assets	$119.9M	2022-12-31	2024-03-19	10-K	24-010402

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.